IKD 01400
Alternative Names: IKD-01400Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator InterK Peptide Therapeutics
- Class Analgesics; Anti-inflammatories; Peptides
- Mechanism of Action Protein kinase G inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Pain in Australia (PO)
- 15 Sep 2020 IKD 01400 is available for licensing as of 15 Sep 2020. www.interk.com.au
- 15 Sep 2020 InterK Peptide Therapeutics has global patent protection for its therapeutic compounds including IKD 01400